
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax Inc. is experiencing growth potential in the post-COVID-19 vaccine market, evidenced by a lucrative licensing deal with Sanofi that could generate up to $1.2 billion and the company capturing 3% market share this season, despite aiming for 5%. The announcement of their 3Q24 financial results indicates effective cost management and a refinement in R&D strategy, positioning the firm to extend its offerings beyond COVID-19 vaccines. Furthermore, Novavax is implementing additional cost reduction measures aimed at lowering operating expenses to below $500 million by 2025, enhancing its long-term operational viability.
Bears say
Novavax Inc reported a significant net loss of $121.3 million for the third quarter of 2024, equating to a loss of $0.76 per share, which was below market expectations. Additionally, the company's revenue forecast for the fourth quarter of 2024 has been notably revised downward from $152.5 million to $88.8 million, reflecting growing uncertainties in product sales. Various risks, including potential failures in clinical trials, regulatory hurdles, and challenges in commercialization and intellectual property, contribute to an overall negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares